Nanoparticle-Enhanced radiation trial aims to shrink tough tumors

NCT ID NCT04789486

Recruiting now Disease control Sponsor: Dana-Farber Cancer Institute Source: ClinicalTrials.gov ↗

First seen May 12, 2026 · Last updated May 13, 2026 · Updated 1 time

Summary

This study tests whether adding AGuIX nanoparticles to precise, MRI-guided radiation therapy can better control centrally located lung tumors and advanced pancreatic cancer. About 100 adults with these cancers will receive the combination treatment. The goal is to find the safest dose and see if it improves tumor shrinkage compared to radiation alone.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Brigham and Women's Hospital
RECRUITING

Boston, Massachusetts, 02115, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact
Dana Farber Cancer Institute
RECRUITING

Boston, Massachusetts, 02115, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact

Conditions

Explore the condition pages connected to this study.

ADVANCED PANCREATIC ADENOCARCINOMA DUCTAL ADENOCARCINOMA OF THE PANCREAS NON-SMALL CELL LUNG CANCER UNRESECTABLE PANCREATIC CANCER